RE:RE:RE:RE:RE:RE:RE:RE:NewsThrough the assistance of the Trade Commission, meetings were held in November 2017 with visiting Japanese hospital representatives in Toronto in advance of CardioComm's visit to Japan. The Company confirmed the likelihood of letters of intent and cooperation agreements to result over the next few months. The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review. These groups are seeking a credible and proven ECG management platform for providing remote ECG monitoring services to hospitals and private patient care management groups. CardioComm's ECG management software is well recognized as a proven telemedicine platform.